医学
博舒替尼
尼罗替尼
帕纳替尼
慢性粒细胞白血病
皮疹
伊马替尼
荟萃分析
内科学
入射(几何)
白血病
肿瘤科
髓系白血病
物理
光学
作者
Li Su,T. Wang,Yu Zhong,Shuqi Dai
出处
期刊:Future Oncology
[Future Medicine]
日期:2023-06-01
卷期号:19 (17): 1215-1227
被引量:2
标识
DOI:10.2217/fon-2022-1008
摘要
Objective: A meta-analysis was conducted to systematically review the risks of all-grade as well as high-grade rash in chronic myelogenous leukemia (CML) patients using different types of BCR-ABL inhibitors. Methods: Literature published between 2000 and April 2022 were searched using PubMed, Cochrane Library, Embase and ClinicalTrials.gov . Results: A total of 12 studies were included for meta-analysis. The results showed that the incidence of all-grade or high-grade rash associated with new-generation BCR-ABL inhibitors had no significant difference compared with a standard dose of imatinib. Subgroup analysis suggested that, compared with imatinib, the incidence of all grades of rash was higher in the nilotinib, bosutinib and ponatinib groups. Conclusion: For CML patients treated with nilotinib, bosutinib and ponatinib, the occurrence of skin toxicity should not be ignored.
科研通智能强力驱动
Strongly Powered by AbleSci AI